<DOC>
	<DOCNO>NCT03049046</DOCNO>
	<brief_summary>Approximately 21 subject amyotrophic lateral sclerosis ( ALS ) randomize ( 6 1 ) receive mouth seven morning dos CC100 placebo 7 day . Subjects require stay Clinic approximately 9 hour follow first last dose . Subjects also mid-week clinic visit contact phone within 3 5 day last dose .</brief_summary>
	<brief_title>CC100 : Phase 1 Multiple-Dose Safety Tolerability Subjects With ALS</brief_title>
	<detailed_description>Primary objective : ass safety tolerability multiple dos orally administer CC100 subject amyotrophic lateral sclerosis ( ALS ) . Secondary objective : determine pharmacokinetics pharmacodynamics CC100 plasma single multiple dos ; determine short-term effect CC100 potential blood-cell ALS biomarkers . Study Design : Phase 1 double-blind , randomize , placebo-controlled multiple-dose three CC100-dose cohort . Approximately 18 subject receive CC100 . Approximately 3 subject randomize placebo ( across 3 cohort ) . Periodic Assessment Committee safety review . Note : Participation exclude subject future CC100 study Criteria Evaluation : Safety Endpoints : Adverse event , blood chemistry , hematology , urinalysis , vital sign , 12-lead ECGs . Pharmacokinetic ( PK ) /Pharmacodynamic ( PD ) : Plasma CC100 concentration ( PK ) . Blood collect baseline subject 's last dose assay potential biomarker ( ) . Stored specimens de-identified combined validate diagnostic tools/assays relate ALS . Statistical Methods : A minimum 6 subject per CC100 dose group 3 placebo-dosed subject ( total across cohort ) consider sufficient evaluate initial safety tolerability cohort . Pharmacokinetic parameter estimate calculate standard noncompartmental method analysis . Absolute bioavailability administration estimate base total area time- concentration curve ( AUC0-âˆž ) .</detailed_description>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Caffeic acid</mesh_term>
	<criteria>Have definite probable ALS force vital capacity &gt; 60 % predict . Men must practice reliable method birth control study 2 week follow study . Women must nonfertile postmenopausal . Riluzole allow dose stable least 30 day . Other allowed medication : lipidlowering drug , antihypertensive , antidepressant , oral medication type II diabetes , estrogen replacement therapy , thyroid replacement therapy , antihistamine , antacid , nonsteroidal antiinflammatory drug ( except indomethacin ) , histamine H2receptor antagonist , protonpump inhibitor , calcium supplement , topical eye medication , topical antibiotic . Greater 250 pound Have serious unstable illness determine investigator . Have current history asthma severe drug allergy pollen allergy . Have serious infectious disease affect brain within precede 5 year ; exist evidence serious infection . Have laboratory test value consider clinically significant determined investigator . Have ECG abnormality clinically significant . Have donate blood ( pint ) receive experimental drug within 30 day prior dose . Have history chronic alcohol drug abuse within past 2 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>